Is HRT Right for Me? A Decision-Making Guide for Perimenopause and Menopause

A practical, evidence-based framework for deciding whether hormone replacement therapy is the right choice for your symptoms, history, and goals. Medically reviewed by the Amsara Health Medical Advisory Board.

TL;DR: The Short Answer

More than 1.3 million women in the United States reach menopause every year, joining the roughly 56 million American women currently in peri- or postmenopause. Globally, an estimated 1.2 billion women will be postmenopausal by 2030. Yet despite this scale, fewer than 1 in 4 symptomatic women receive treatment, and only 6.8% of US medical residents report feeling adequately prepared to manage menopause care.

Hormone Replacement Therapy (HRT) is appropriate for most healthy women under 60 (or within 10 years of menopause) who have bothersome menopause symptoms. The 2026 HHS removal of the longstanding FDA "black box" warning, which the agency officially characterized as "misleading," reflects two decades of evidence showing the benefits outweigh the risks for most women in this window.

The most important step you can take today, regardless of where you land on HRT: start tracking your symptoms. Patterns invisible day-to-day become unmistakable over weeks, and turn a 15-minute clinical appointment into a precision conversation. The Harmoni by The Pause app is purpose-built for exactly this.

The Menopause Reality: Why This Decision Matters Now

Menopause is no longer a topic women whisper about, but the medical system has not caught up with the scale of the need. The numbers tell the story.

How Many Women Are Navigating This

• 1.3 million US women enter menopause every year
• ~56 million US women are currently in peri- or postmenopause
• 1.2 billion women globally will be postmenopausal by 2030
• Average age of natural menopause in the US: 51 years
• Average duration of perimenopause: 4 years, ranging up to 10 years
• Women now spend roughly one-third of their lives in postmenopause

How Common Symptoms Actually Are

• Up to 85% of women experience menopause symptoms
• ~75% experience hot flashes and night sweats (vasomotor symptoms)
• Median duration of hot flashes: 7.4 years, over 14 years for some women
• 40 to 60% experience clinically significant sleep disruption
• 50 to 84% experience genitourinary syndrome of menopause (GSM)
• ~60% report cognitive symptoms including "brain fog"
• Perimenopausal women have a 2 to 4× higher risk of new-onset depression than premenopausal women

The Treatment Gap

• Fewer than 25% of symptomatic women receive any treatment
• HRT use in the US dropped from ~40% to under 5% after the 2002 WHI publication, despite later reanalysis showing the original interpretation overstated risks for most women
• Only 6.8% of US medical residents feel adequately prepared to manage menopause
• An estimated $1.8 billion in lost work time annually in the US is attributable to untreated menopause symptoms

This is the context for your decision. Whether HRT is right for you is a question worth answering carefully, and that begins with data.

Step 1: Identify Your Symptoms

The first question is not "should I take HRT" but "what am I actually trying to treat?" The most common menopause symptoms HRT addresses, and their prevalence in research, include:

• Vasomotor symptoms (hot flashes, night sweats): 75% of women; median duration 7.4 years
• Genitourinary syndrome of menopause (GSM): 50 to 84% of postmenopausal women experience vaginal dryness, painful sex, recurrent UTIs, or urinary urgency
• Sleep disruption: 40 to 60% of women, often driven by night sweats
• Mood symptoms: ~40% experience anxiety, low mood, or irritability; perimenopause is a window of elevated depression risk
• Cognitive symptoms ("brain fog," word-finding difficulty): ~60%
• Joint and muscle aches: reported by more than half of midlife women
• Skin and hair changes
• Loss of libido

Some symptoms, moderate-to-severe hot flashes and GSM in particular, respond very well to HRT. Others may have multiple contributors and benefit from a broader approach.

But here's the critical issue: most women dramatically underestimate the severity and frequency of their symptoms when asked at a single point in time. The brain normalizes the new baseline. Recall of episodic symptoms, especially hot flashes, sleep disruption, and mood, is unreliable in research studies. This is why systematic tracking matters more than most women realize.

Step 2: Check the Timing Window

The single most important factor in the HRT risk-benefit calculation is when you start it relative to menopause.

• Under 60 and within 10 years of final menstrual period: Benefits generally outweigh risks for healthy women
• Over 60 or more than 10 years past menopause: More individualized assessment needed
• Premature ovarian insufficiency (under 40): HRT typically recommended until at least age 51

This is the "timing hypothesis," the consensus position of The Menopause Society, ACOG, the Endocrine Society, and the British Menopause Society. The 2016 ELITE trial in the New England Journal of Medicine found that estradiol slowed progression of subclinical atherosclerosis in women within 6 years of menopause, but not in women more than 10 years past menopause.

Step 3: Review Your Medical History

HRT is generally not recommended for women with:

• A personal history of breast, endometrial, or other hormone-sensitive cancer
• A history of stroke, heart attack, or coronary artery disease
• A history of blood clots (VTE) or known clotting disorders
• Active liver disease
• Unexplained vaginal bleeding (until evaluated)

For some women in these categories, transdermal estrogen, which carries approximately half the VTE risk of oral estrogen, or local vaginal estrogen (minimal systemic absorption) may still be appropriate after specialist consultation.

Step 4: Understand Your Options

Hormonal Options

• Systemic estrogen: patches, gels, sprays, oral tablets, for women without a uterus, or paired with a progestogen for women with a uterus
• Combined estrogen + progestogen therapy: for women with a uterus; reduces hot flash frequency by 70 to 90%
• Local vaginal estrogen: creams, tablets, or rings, for GSM-only symptoms, with minimal systemic absorption
• Testosterone (off-label): low-dose transdermal for persistent low libido

Non-Hormonal Prescription Options

• Fezolinetant (Veozah): an NK3 receptor antagonist FDA-approved in 2023, reducing moderate-to-severe vasomotor symptoms by approximately 60% in phase 3 trials
• SSRIs and SNRIs: paroxetine (the only FDA-approved SSRI for hot flashes), venlafaxine, escitalopram
• Gabapentin: particularly helpful for night sweats and sleep
• Oxybutynin: reduces hot flash frequency
• Ospemifene: a selective estrogen receptor modulator for painful intercourse

Non-Pharmaceutical Approaches

These can be used alone or alongside HRT/non-hormonal medications:

• Cognitive behavioral therapy (CBT): strong evidence for vasomotor symptoms, sleep, and mood
• Resistance training: supports muscle, bone, and metabolic health
• Protein pacing and adequate protein intake: supports body composition
• Cooling strategies
• Mindfulness-based stress reduction (MBSR)
• Acupuncture: modest evidence for vasomotor symptoms

Step 5: Have the Right Conversation With Your Clinician

The average US primary care appointment lasts just 15 to 18 minutes. For a complex, multi-symptom condition like menopause, addressed by a clinician who, statistically, has not been trained in menopause management, that's not enough time to wing it.

If you're uncertain about HRT or your symptoms are not being adequately addressed, consider:

• Finding a Menopause Society Certified Practitioner (MSCP)
• Bringing weeks of symptom tracking data to your appointment (the Harmoni by The Pause app generates a clinician-ready report you can share directly)
• Asking specifically about transdermal options if you have cardiovascular risk factors
• Asking about dose adjustment if your initial regimen isn't working (finding the right formulation often takes 2 to 3 months)

Questions to Ask Your Provider

• Based on my symptoms and history, am I a candidate for HRT?
• What is your recommendation: estrogen-only, combined, or local vaginal?
• Oral or transdermal, and why?
• What are the risks and benefits specifically for me?
• How will we monitor and reassess?
• What are my non-hormonal options if HRT isn't right for me?

Why Symptom Tracking Transforms Your Menopause Care

If you take only one action after reading this article, make it starting a symptom tracking practice. Here's why it matters more than most women realize.

The Data Problem in Menopause Care

A typical menopause appointment relies on a patient recalling symptoms from the past few weeks or months. Research consistently finds that patient recall of episodic symptoms is unreliable: people remember peaks and recent events, not patterns. This is especially true for hot flashes, sleep disruption, and mood symptoms, which fluctuate dramatically across days, weeks, and the menstrual cycle (during perimenopause).

This matters because treatment decisions depend on patterns, not snapshots:

• Are hot flashes daily? Weekly? Worse before your period?
• Is sleep disruption tied to night sweats, or independent?
• Are mood symptoms cyclical or constant?
• Is brain fog isolated, or paired with poor sleep?

Without data, both you and your clinician are guessing.

What the Research Shows About Tracking

• Patient-generated health data shared with providers is associated with more targeted treatment plans, improved patient-clinician communication, and better health outcomes across chronic conditions
• Digital health interventions for women's health have been shown to improve symptom awareness and treatment adherence
• Women who arrive at menopause appointments with documented symptom data report higher satisfaction with care and faster identification of effective treatment

How Harmoni by The Pause Helps

The Harmoni by The Pause app is designed specifically for the symptoms women in perimenopause and menopause actually experience, not generic wellness tracking.

• Log symptoms in seconds: hot flashes, sleep, mood, energy, cycle (for perimenopause), and more
• Visualize your patterns: daily, weekly, and monthly trends
• Generate a clinician-ready report: share weeks of data with your provider in a single document
• Track treatment response: measure objectively whether HRT, non-hormonal medication, or lifestyle changes are working

Most women see meaningful patterns within 2 to 4 weeks of consistent tracking. That's the window between deciding to track and walking into a far better appointment.

What the HHS Removal of the HRT Black Box Warning Means for You

In a major policy shift, the U.S. Department of Health and Human Services (HHS) announced the removal of the FDA "black box" warnings from hormone replacement therapy products, officially characterizing the warnings (in place since 2003) as "misleading." The action followed the July 2025 FDA Expert Panel on Menopause led by Commissioner Dr. Marty Makary, at which leading menopause specialists confirmed what the field has argued for years: the original warnings were based on data from older women, failed to distinguish between oral and transdermal delivery, and inappropriately applied to low-dose vaginal estrogen.

For patients, this means:

• Reduced stigma around starting HRT
• Easier access to local vaginal estrogen for GSM, where the warning was particularly inappropriate
• More nuanced conversations about individualized risk-benefit
• Greater alignment between FDA labeling and current clinical guidelines

It does not change the fundamental decision-making framework, but it does remove a longstanding regulatory barrier that prevented many women from receiving appropriate care.

Frequently Asked Questions

How do I know if my menopause symptoms are bad enough for HRT?

If your symptoms are affecting your sleep, mood, work, relationships, or quality of life, they warrant evaluation. There is no severity threshold required to consider HRT. Tracking your symptoms for 2 to 4 weeks with an app like Harmoni gives you objective data to bring to the conversation, particularly important given that fewer than 1 in 4 symptomatic women currently receive treatment.

Can I try HRT and stop if it doesn't work?

Yes. HRT is not a lifetime commitment. Most regimens can be safely discontinued, typically by tapering. Many women trial HRT for 3 to 6 months to assess benefit, and tracking symptoms throughout the trial is the most reliable way to measure whether it's working.

Is HRT covered by insurance?

FDA-approved HRT is generally covered by insurance, though specific formulations and brands vary by plan. Compounded bioidentical hormones are typically not covered and are not recommended by major medical societies.

What are the non-hormonal alternatives to HRT for hot flashes?

Evidence-based non-hormonal options include fezolinetant (Veozah, FDA-approved 2023, ~60% symptom reduction), SSRIs and SNRIs (paroxetine, venlafaxine), gabapentin, oxybutynin, cognitive behavioral therapy (CBT), and lifestyle interventions.

What if my doctor says I'm too old for HRT?

This may reflect outdated guidance. Current evidence supports individualized assessment rather than blanket age cutoffs. With only 6.8% of US medical residents reporting adequate menopause training, a second opinion from a Menopause Society Certified Practitioner may be warranted.

How much symptom data do I need before my appointment?

Research and clinical experience suggest 2 to 4 weeks of consistent tracking is enough to identify meaningful patterns. The longer you track, the better, but don't delay your appointment waiting for "perfect" data.

The Bottom Line

HRT is a powerful, evidence-based tool, not a cure-all and not a danger to be avoided. For most healthy women in the menopause transition, the benefits substantially outweigh the risks when treatment is started within the appropriate window and matched to individual needs.

The 2026 HHS removal of the misleading FDA warnings is a long-overdue correction. But the bigger barrier to good menopause care isn't regulatory, it's information. With 56 million American women in peri- or postmenopause, fewer than 25% receiving treatment, and only 6.8% of medical trainees prepared to deliver care, the gap between need and care is enormous.

The right decision is personal, informed, and made with a clinician who specializes in menopause care. At Amsara Health, we provide that expertise, integrating evidence-based hormonal and non-hormonal therapies with nutrition, movement, and lifestyle support designed for the menopause transition.

Your next step: Start tracking your symptoms today with Harmoni by The Pause. Two to four weeks of data will transform your next conversation with your clinician, whether that conversation is about HRT, non-hormonal options, or a combined approach.

References

1. The Menopause Society. Menopause FAQs: Understanding the Symptoms. Available at: menopause.org.
2. North American Menopause Society. Menopause Practice: A Clinician's Guide, 6th Edition. 2019.
3. World Health Organization. Menopause. Fact sheet. October 2022.
4. Kingsberg SA, Schaffir J, Faught BM, et al. Female sexual health: barriers to optimal outcomes and a roadmap for improved patient-clinician communications. Journal of Women's Health. 2019;28(4):432-443.
5. Kling JM, MacLaughlin KL, Schnatz PF, et al. Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents: a cross-sectional survey. Mayo Clinic Proceedings. 2019;94(2):242-253.
6. The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
7. Gold EB. The timing of the age at which natural menopause occurs. Obstetrics and Gynecology Clinics of North America. 2011;38(3):425-440.
8. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10. Journal of Clinical Endocrinology & Metabolism. 2012;97(4):1159-1168.
9. Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008;11(1):32-43.
10. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition. American Journal of Public Health. 2006;96(7):1226-1235.
11. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. 2015;175(4):531-539.
12. Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstetrics and Gynecology Clinics of North America. 2011;38(3):567-586.
13. Portman DJ, Gass ML. Genitourinary syndrome of menopause. Menopause. 2014;21(10):1063-1068.
14. Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850-1857.
15. Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: SWAN. Psychological Medicine. 2011;41(9):1879-1888.
16. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use. Obstetrics & Gynecology. 2012;120(3):595-603.
17. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA. 2017;318(10):927-938.
18. Faubion SS, Enders F, Hedges MS, et al. Impact of menopause symptoms on women in the workplace. Mayo Clinic Proceedings. 2023;98(6):833-845.
19. Magliano M. Menopausal arthralgia: fact or fiction. Maturitas. 2010;67(1):29-33.
20. Stone AA, Schwartz JE, Broderick JE, Shiffman SS. Variability of momentary pain predicts recall of weekly pain. Pain. 2010;149(1):143-148.
21. Cohen DJ, Keller SR, Hayes GR, et al. Integrating patient-generated health data into clinical care settings. JMIR Human Factors. 2016;3(2):e26.
22. Petersen C. Patient-generated health data: a pathway to enhanced long-term cancer survivorship. Journal of the American Medical Informatics Association. 2016;23(3):456-461.
23. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. 2016;374(13):1221-1231.
24. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes. JAMA. 2013;310(13):1353-1368.
25. ESHRE Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926-937.
26. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015;100(11):3975-4011.
27. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ. 2019;364:k4810.
28. Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms. Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1981-1997.
29. Hunter MS. Cognitive behavioral therapy for menopausal symptoms. Climacteric. 2021;24(1):51-56.
30. Neprash HT, Everhart A, McAlpine D, et al. Measuring primary care exam length using electronic health record data. Medical Care. 2021;59(1):62-66.
31. Tighe SA, Ball K, Kensing F, et al. Toward a digital platform for the self-management of noncommunicable disease. Journal of Medical Internet Research. 2020;22(10):e16774.
32. Manson JE, Kaunitz AM. Menopause management, getting clinical care back on track. New England Journal of Medicine. 2016;374(9):803-806.
33. U.S. Department of Health and Human Services. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA Press Announcement.
34. U.S. Food and Drug Administration. FDA Expert Panel on Menopause. July 17, 2025.
35. Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy. Menopause. 2015;22(9):926-936.

This article is for educational purposes and does not constitute medical advice. Decisions about menopause treatment are individualized and should be made in consultation with a qualified clinician. Speak with your Amsara Health provider to determine the right approach for you.